Compare
McCormick & Co Inc vs Medifast Inc
| Latest fiscal year | McCormick & Co Inc MKC | Medifast Inc MED |
|---|---|---|
| Year ended | 2025-11-30 | 2025-12-31 |
| Revenue | $6.84B | $385.79M |
| Revenue growth (YoY) | +1.7% | -36.0% |
| Gross margin | 37.9% | 71.3% |
| Operating margin | 15.7% | -3.7% |
| Net margin | 11.5% | -4.8% |
| Net income | $789.40M | -$18.67M |
| EPS (Diluted) | $2.93 | -$1.70 |
| Operating cash flow | $962.20M | $6.86M |
| Free cash flow | $740.40M | $1.25M |
| Cash & equivalents | $95.90M | $89.30M |
| Total assets | $13.20B | $247.97M |
| Total liabilities | $7.43B | $49.05M |
| Shareholders' equity | $5.77B | $198.92M |
| Return on year-end equity | 13.7% | -9.4% |
| Shares outstanding | n/a | 10.99M |
Revenue, most recent five fiscal years
| Fiscal year | McCormick & Co Inc | Medifast Inc |
|---|---|---|
| Latest | $6.84B Ended 2025-11-30 | $385.79M Ended 2025-12-31 |
| 1 year earlier | $6.72B Ended 2024-11-30 | $602.46M Ended 2024-12-31 |
| 2 years earlier | $6.66B Ended 2023-11-30 | $1.07B Ended 2023-12-31 |
| 3 years earlier | $6.35B Ended 2022-11-30 | $1.60B Ended 2022-12-31 |
| 4 years earlier | $6.32B Ended 2021-11-30 | $1.53B Ended 2021-12-31 |